KR100920749B1 - 초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 - Google Patents
초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 Download PDFInfo
- Publication number
- KR100920749B1 KR100920749B1 KR1020070099519A KR20070099519A KR100920749B1 KR 100920749 B1 KR100920749 B1 KR 100920749B1 KR 1020070099519 A KR1020070099519 A KR 1020070099519A KR 20070099519 A KR20070099519 A KR 20070099519A KR 100920749 B1 KR100920749 B1 KR 100920749B1
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- image
- cells
- apoptosis
- fluorescent
- Prior art date
Links
- 238000000701 chemical imaging Methods 0.000 title claims abstract description 42
- 238000000423 cell based assay Methods 0.000 title abstract description 4
- 238000004445 quantitative analysis Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000004458 analytical method Methods 0.000 claims abstract description 29
- 238000003705 background correction Methods 0.000 claims abstract description 13
- 238000000684 flow cytometry Methods 0.000 claims abstract description 12
- 230000003287 optical effect Effects 0.000 claims abstract description 5
- 230000006907 apoptotic process Effects 0.000 claims description 67
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 43
- 230000017074 necrotic cell death Effects 0.000 claims description 41
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 26
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 26
- 229940127093 camptothecin Drugs 0.000 claims description 26
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 26
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 23
- 230000030833 cell death Effects 0.000 claims description 23
- 239000007850 fluorescent dye Substances 0.000 claims description 23
- 229960004025 sodium salicylate Drugs 0.000 claims description 23
- 230000006721 cell death pathway Effects 0.000 claims description 17
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 13
- 229940117954 naringenin Drugs 0.000 claims description 13
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 13
- 235000007625 naringenin Nutrition 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 239000000049 pigment Substances 0.000 claims description 10
- 230000003595 spectral effect Effects 0.000 claims description 10
- 238000010186 staining Methods 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 7
- 238000003570 cell viability assay Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims description 4
- 239000000158 apoptosis inhibitor Substances 0.000 claims description 4
- 238000010191 image analysis Methods 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 3
- 239000004973 liquid crystal related substance Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 abstract description 15
- 238000007877 drug screening Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 218
- 206010028851 Necrosis Diseases 0.000 description 33
- 239000002096 quantum dot Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 230000001640 apoptogenic effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000036457 multidrug resistance Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000003026 viability measurement method Methods 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- FTVWIRXFELQLPI-UHFFFAOYSA-N naringenin Chemical compound C1=CC(O)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-UHFFFAOYSA-N 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000324 minimal toxicity Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 238000002970 ATP quantitation Methods 0.000 description 1
- 101710172503 Chemokine-binding protein Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003709 image segmentation Methods 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 respectively Chemical compound 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J3/1256—Generating the spectrum; Monochromators using acousto-optic tunable filter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/88—Investigating the presence of flaws or contamination
- G01N21/8851—Scan or image signal processing specially adapted therefor, e.g. for scan signal adjustment, for detecting different kinds of defects, for compensating for structures, markings, edges
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/0004—Microscopes specially adapted for specific applications
- G02B21/002—Scanning microscopes
- G02B21/0024—Confocal scanning microscopes (CSOMs) or confocal "macroscopes"; Accessories which are not restricted to use with CSOMs, e.g. sample holders
- G02B21/0052—Optical details of the image generation
- G02B21/0076—Optical details of the image generation arrangements using fluorescence or luminescence
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/06—Means for illuminating specimens
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B26/00—Optical devices or arrangements for the control of light using movable or deformable optical elements
- G02B26/007—Optical devices or arrangements for the control of light using movable or deformable optical elements the movable or deformable optical element controlling the colour, i.e. a spectral characteristic, of the light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J2003/1213—Filters in general, e.g. dichroic, band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
- G01J3/4406—Fluorescence spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
- G01N2015/144—Imaging characterised by its optical setup
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N2021/6463—Optics
- G01N2021/6471—Special filters, filter wheel
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/067—Electro-optic, magneto-optic, acousto-optic elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2223/00—Investigating materials by wave or particle radiation
- G01N2223/40—Imaging
- G01N2223/418—Imaging electron microscope
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Astronomy & Astrophysics (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
샘플 | 세포 생존능력(%) | |
도 C1 | 대조군 | 92 |
도 C2 | 2.5 mM 살리실산나트륨 | 83 |
도 C3 | 5 mM 살리실산나트륨 | 69 |
도 C4 | 10 mM 살리실산나트륨 | 45 |
퍼센트 사분면 통계: 총 세포 372 | |||||||||
FC | HSIA | FC | HSIA | FC | HSIA | FC | HSIA | ||
도면 | 샘플 | UL | UR | LL | LR | ||||
도 6 a1) | 대조군 | 4.30 | 0.00 | 0.00 | 1.10 | 97.72 | 92.20 | 1.80 | 3.50 |
도 6 a2) | M-10 | 0.21 | 0.80 | 25.62 | 3.76 | 10.30 | 44.89 | 63.87 | 50.53 |
도 6 a3) | M-10 & Z-IEDT -FMK | 0.03 | 0.27 | 5.08 | 2.41 | 67.25 | 66.66 | 26.92 | 30.64 |
도 6 a4) | M-5 | 0.00 | 1.61 | 9.06 | 5.64 | 53.93 | 50.53 | 37.01 | 42.20 |
도 6 a5) | M-5 & CAM-50 | 0.12 | 0.80 | 13.65 | 4.57 | 41.61 | 36.82 | 44.62 | 57.79 |
Claims (29)
- 샘플을 놓는 플랫폼;이온 레이저 빔을 방출하는 이온 레이저 광원 또는 필터를 채용한 백색광원;상기 이온 레이저 광원 또는 상기 백색광원으로부터 방출된 입사광의 입사량을 줄이는 ND(neutal density) 필터;상기 ND 필터를 통과한 입사광을 정제하는 간섭필터(interference filter);상기 간섭필터를 통과한 입사광을 대물렌즈 방향으로 반사하고 대물렌즈로부터 모아진 형광빔을 통과시키는 이색 반사경(dichromatic mirror);입사광의 초점을 맞추고 상기 샘플로부터 여기된 형광빔을 모으는 대물렌즈;상기 이색 반사경을 통과한 형광빔을 반사하는 프리즘;상기 프리즘을 통과한 형광빔의 직경을 줄이는 렌즈;상기 렌즈를 통과한 형광빔의 파장을 시간에 따라 조절할 수 있는 가변형 필터;상기 가변형 필터를 통과한 빔의 흩어지는 것을 방지하는 롱-패스 필터(long-pass filter);상기 롱-패스 필터를 통과한 형광빔을 검출하는 CCD 카메라; 및상기 CCD 카메라에 의해 검출한 형광빔의 이미지 취득 및 분석 소프트웨어를 갖춘 컴퓨터 시스템으로 이루어진 초분광 이미지 시스템.
- 삭제
- 제 1항에 있어서, 가변형 필터는 음향광학 파장 가변형 필터(Acousto-Optic Tunable Filter, AOTF) 또는 액정 가변형 필터(Liquid crystal tunable filter, LCTF)인 것을 특징으로 하는 초분광 이미지 시스템.
- 제 3항에 있어서, 음향광학 파장 가변형 필터(Acousto-Optic Tunable Filter, AOTF)는 463 nm ~ 근 적외광에 이르는 스펙트럼 부위를 0.1 ~ 30 nm 파장 간격으로 초당 하나의 이미지 프레임으로 스캐닝하는 것을 특징으로 하는 초분광 이미지 시스템.
- 1) 공초점 현미경의 샘플 플랫폼에 세포시료를 올려놓은 다음, 대물렌즈의 높이를 조절하여, 초점을 맞춘 이미지 및 초점을 경미하게 흐린 이미지를 CCD 카메라를 통해 취득하고 배경 보정을 위하여 배지만 포함된 배지시료에 대한 이미지를 CCD 카메라를 통해 취득하여 상기 공초점 현미경에 연결된 컴퓨터 시스템을 이용하여 파일로 저장하는 단계;2) 상기 단계 1)을 통해 저장된 파일을 상기 컴퓨터 시스템에 탑재된 이미지 분석 소프트웨어를 통해 로딩한 후, 상기 초점을 경미하게 흐린 이미지에 대한 배경보정을 수행하는 단계;3) 상기 이미지 분석 소프트웨어를 통해 상기 단계 1)에서 배경보정된 이미지에 대하여 역치 조정을 수행하는 단계;4) 상기 이미지 분석 소프트웨어를 통해 상기 단계 3)에서 역치 조정된 이미지로부터 원하지 않는 물체를 제거하는 단계;5) 상기 이미지 분석 소프트웨어를 통해 상기 단계 4)에서 원하지 않는 물체가 제거된 이미지로부터 원하는 물체인 세포의 이미지 형성을 위한 가상(mask)을 형성하는 단계;6) 상기 이미지 분석 소프트웨어를 통해 상기 단계 5)의 가상으로부터 세포 주변 이미지를 형성하는 단계; 및7) 상기 이미지 분석 소프트웨어를 통해 상기 세포 주변 이미지를 이용하여 세포수를 계수하는 단계를 포함하는 세포 분석방법.
- 제 5항에 있어서, 분석대상 세포수는 300 내지 2000개인 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 세포사멸 및 세포괴사를 동시에 모니터하는 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 상대적인 형광 강도를 이용하여 세포자살 및 세포괴사의 형태 감별을 하는 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 3차원(3D)적 시각화 효과를 이용하여 세포자살 및 세포괴사의 형태 감별을 하는 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 이미지 분석 소프트웨어는 메타모프®(MetaMorph®)인 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 상기 공초점 현미경은 제 1항의 이미지 분석 시스템인 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 원하지 않는 물체의 제거는 이미지의 너비 감소 또는 밝기를 이용하여 수행하는 것을 특징으로 하는 분석방법.
- 제 5항에 있어서, 세포수의 계수는 광학 밀도(optical density), 평균 그레이 값(average gray value), Z 위치(Z 위치), 각(angle), 거리(distance), 부위(area), 너비(width), 경과 시간(elapsed time), 단계 레벨(stage label), 파장(wavelength), 부위 레벨(region level), 강도(intensity S/N), 역치 부위(threshod area)로 이루어진 군으로부터 선택되는 매개변수를 이용하는 것을 특징으로 하는 분석방법.
- 1) 세포에 세포죽음 경로를 유도하는 시약을 처리하는 단계;2) 상기 세포를 세포괴사 또는 세포사멸에 특이적인 형광성 색소로 염색시키는 단계; 및3) 상기 제 5항의 분석방법으로 전체 세포수 및 죽은 세포수를 계수하는 단계를 포함하는 세포 생존능력 분석방법(cell viability assay).
- 제 14항에 있어서, 세포는 백혈병 세포인 HL-60인 것을 특징으로 하는 세포 생존능력 분석방법.
- 제 14항에 있어서, 상기 단계 1)의 세포죽음 경로를 유도하는 시약은 살리실산나트륨(sodium salicylate), 나린제닌(naringenin) 또는 캄토테신(camptothecin)인 것을 특징으로 하는 세포 생존능력 분석방법.
- 제 14항에 있어서, 상기 단계 2)의 세포사멸에 특이적인 형광성 색소는 Qdot-스트렙타비딘 결합물(Qdot-streptavidin conjugate)이고 세포괴사에 특이적인 형광성 색소는 프로피디움 요오드화물(propidium iodide)인 것을 특징으로 하는 세포 생존능력 분석방법.
- 1) 세포에 세포죽음 경로를 유도하는 시약 및 피검 물질을 처리하는 단계;2) 상기 세포를 세포괴사 또는 세포사멸에 특이적인 형광성 색소로 염색시키는 단계;3) 상기 제 5항의 분석방법으로 전체 세포수와 죽은 세포수를 계수하는 단계; 및4) 피검 물질을 처리하지 않은 대조군과 비교하여 죽은 세포수가 감소된 피검 물질을 선별하는 단계를 포함하는 세포사멸 억제제의 스크리닝방법.
- 제 18항에 있어서, 상기 단계 1)의 세포는 백혈병 세포인 HL-60인 것을 특징으로 하는 스크리닝방법.
- 제 18항에 있어서, 상기 단계 1)의 세포죽음 경로를 유도하는 시약은 살리실산나트륨(sodium salicylate), 나린제닌(naringenin) 또는 캄토테신(camptothecin)인 것을 특징으로 하는 스크리닝방법.
- 제 18항에 있어서, 상기 단계 2)의 세포사멸에 특이적인 형광성 색소는 Qdot-스트렙타비딘 결합물(Qdot-streptavidin conjugate)이고 세포괴사에 특이적인 형광성 색소는 프로피디움 요오드화물(propidium iodide)인 것을 특징으로 하는 스 크리닝방법.
- 1) 세포를 형광성 색소로 염색시키는 단계; 및2) 상기 제 5항의 분석방법으로 형광성 색소로 염색된 세포를 계수하는 단계를 포함하는 유세포 분석방법.
- 제 22항에 있어서, 형광성 색소는 세포사멸에 특이적인 형광성 색소 및/또는 세포괴사에 특이적인 형광성 색소인 것을 특징으로 하는 유세포 분석방법.
- 제 23항에 있어서, 상기 세포사멸에 특이적인 형광성 색소는 Qdot-스트렙타비딘 결합물(Qdot-streptavidin conjugate)인 것을 특징으로 하는 유세포 분석방법.
- 제 23항에 있어서, 세포괴사에 특이적인 형광성 색소는 프로피디움 요오드화물인 것을 특징으로 하는 유세포 분석방법.
- 제 22항에 있어서, 세포는 두 가지 이상의 항체로 표지된 것을 특징으로 하는 유세포 분석방법.
- 1) 세포에 피검 물질을 처리하는 단계;2) 상기 세포를 세포괴사 또는 세포사멸에 특이적인 형광 색소로 염색하는 단계;3) 상기 제 5항의 분석방법으로 전체 세포수와 죽은 세포수를 계수하는 단계; 및4) 피검 물질을 처리하지 않은 대조군과 비교하여 죽은 세포수가 증가된 피검 물질을 선별하는 단계를 포함하는 세포괴사 또는 세포사멸 촉진제의 스크리닝방법.
- 제 27항에 있어서, 세포괴사에 특이적인 형광성 색소는 프로피디움 요오드화물인 것을 특징으로 하는 스크리닝방법
- 제 27항에 있어서, 상기 세포사멸에 특이적인 형광성 색소는 Qdot-스트렙타 비딘 결합물(Qdot-streptavidin conjugate)인 것을 특징으로 하는 유세포 분석방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070099519A KR100920749B1 (ko) | 2007-10-02 | 2007-10-02 | 초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070099519A KR100920749B1 (ko) | 2007-10-02 | 2007-10-02 | 초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090034245A KR20090034245A (ko) | 2009-04-07 |
KR100920749B1 true KR100920749B1 (ko) | 2009-10-07 |
Family
ID=40760256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070099519A KR100920749B1 (ko) | 2007-10-02 | 2007-10-02 | 초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100920749B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012157979A2 (ko) * | 2011-05-19 | 2012-11-22 | 서울대학교 산학협력단 | 휴대용 하이퍼멀티컬러 이미징 광학모듈 및 마이크로비드 컬러코딩 기반 키나아제 저해 약물 스크리닝 시스템 |
KR101619834B1 (ko) * | 2016-01-27 | 2016-05-11 | (주)아세아항측 | 암실 초분광 리니어 스캐닝 시스템 |
CN106769805A (zh) * | 2017-01-22 | 2017-05-31 | 江西特康科技有限公司 | 细胞计数分类装置 |
KR20170094288A (ko) * | 2014-12-05 | 2017-08-17 | 케이엘에이-텐코 코포레이션 | 분광 빔 프로파일 계측학 |
KR102641004B1 (ko) | 2022-12-21 | 2024-02-27 | 주식회사 리퓨터 | 자동 근적외선 초분광 촬영 시스템 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8830451B1 (en) | 2010-05-07 | 2014-09-09 | Stc.Unm | Multinode acoustic focusing for parallel flow cytometry analysis applications |
US9074977B2 (en) | 2010-05-07 | 2015-07-07 | Stc.Unm | Multinode acoustic focusing for parallel flow cytometry analysis applications |
US9274042B2 (en) | 2010-05-07 | 2016-03-01 | Stc.Unm | Spatially correlated light collection from multiple sample streams excited with a line focused light source |
JP6110484B2 (ja) * | 2012-06-21 | 2017-04-05 | エスティーシー. ユーエヌエムStc.Unm | ラインフォーカシング式光源で励起した多数のサンプル流れからの空間相関集光 |
JP2014115151A (ja) * | 2012-12-07 | 2014-06-26 | Shimadzu Corp | 光イメージング装置 |
KR101870170B1 (ko) * | 2016-11-18 | 2018-06-22 | 한국지질자원연구원 | 암석 또는 광물 샘플의 초분광 영상 자료 획득을 위한 초분광 영상 획득 장치 |
KR101872240B1 (ko) * | 2017-01-26 | 2018-06-29 | 서울대학교산학협력단 | 가시광/근적외선 초분광 현미경기반 영상 측정장치를 이용한 영상 측정방법 |
EP3688441A4 (en) * | 2017-09-28 | 2020-11-11 | Becton, Dickinson and Company | METHOD OF ALIGNING A LASER WITH A FLOW FLOW AND SYSTEMS THEREOF |
KR102498122B1 (ko) | 2017-11-21 | 2023-02-09 | 삼성전자주식회사 | 분광 장치와, 분광 방법, 및 생체신호 측정장치 |
CN113155578B (zh) * | 2017-12-29 | 2024-08-02 | 乔治洛德方法研究和开发液化空气有限公司 | 一种丝状微生物的染色方法及其用途 |
CN110530783B (zh) * | 2018-05-24 | 2023-12-15 | 深圳市帝迈生物技术有限公司 | 用于流式细胞仪的侧向光束收集方法、装置及流式细胞仪 |
CN110824684B (zh) * | 2019-10-28 | 2020-10-30 | 华中科技大学 | 一种高速立体三维多模态成像系统和方法 |
CN118518565A (zh) * | 2023-02-14 | 2024-08-20 | 赵精晶 | 基于成像流式细胞术的高通量药物筛选方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020075672A (ko) * | 2001-03-27 | 2002-10-05 | 임채헌 | 광원의 파장 분석용 필터박스 및 필터박스를 이용한 세포분석 장치 |
KR20050093490A (ko) * | 2004-03-19 | 2005-09-23 | 광주과학기술원 | 점진적인 굴절률 분포를 지닌 광자결정과 그의 제조방법 |
WO2007038650A2 (en) | 2005-09-26 | 2007-04-05 | Chemimage Corporation | Hyperspectral visible absorption imaging of molecular probes and dyes in biomaterials |
-
2007
- 2007-10-02 KR KR1020070099519A patent/KR100920749B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020075672A (ko) * | 2001-03-27 | 2002-10-05 | 임채헌 | 광원의 파장 분석용 필터박스 및 필터박스를 이용한 세포분석 장치 |
KR20050093490A (ko) * | 2004-03-19 | 2005-09-23 | 광주과학기술원 | 점진적인 굴절률 분포를 지닌 광자결정과 그의 제조방법 |
WO2007038650A2 (en) | 2005-09-26 | 2007-04-05 | Chemimage Corporation | Hyperspectral visible absorption imaging of molecular probes and dyes in biomaterials |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012157979A2 (ko) * | 2011-05-19 | 2012-11-22 | 서울대학교 산학협력단 | 휴대용 하이퍼멀티컬러 이미징 광학모듈 및 마이크로비드 컬러코딩 기반 키나아제 저해 약물 스크리닝 시스템 |
WO2012157979A3 (ko) * | 2011-05-19 | 2013-03-21 | 서울대학교 산학협력단 | 휴대용 하이퍼멀티컬러 이미징 광학모듈 및 마이크로비드 컬러코딩 기반 키나아제 저해 약물 스크리닝 시스템 |
KR101303815B1 (ko) | 2011-05-19 | 2013-09-10 | 서울대학교산학협력단 | 휴대용 하이퍼멀티컬러 이미징 광학모듈 및 마이크로비드 컬러코딩 기반 키나아제 저해 약물 스크리닝 시스템 |
KR20170094288A (ko) * | 2014-12-05 | 2017-08-17 | 케이엘에이-텐코 코포레이션 | 분광 빔 프로파일 계측학 |
KR102386664B1 (ko) * | 2014-12-05 | 2022-04-13 | 케이엘에이 코포레이션 | 분광 빔 프로파일 계측 |
KR101619834B1 (ko) * | 2016-01-27 | 2016-05-11 | (주)아세아항측 | 암실 초분광 리니어 스캐닝 시스템 |
CN106769805A (zh) * | 2017-01-22 | 2017-05-31 | 江西特康科技有限公司 | 细胞计数分类装置 |
CN106769805B (zh) * | 2017-01-22 | 2019-06-18 | 江西特康科技有限公司 | 细胞计数分类装置 |
KR102641004B1 (ko) | 2022-12-21 | 2024-02-27 | 주식회사 리퓨터 | 자동 근적외선 초분광 촬영 시스템 |
Also Published As
Publication number | Publication date |
---|---|
KR20090034245A (ko) | 2009-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100920749B1 (ko) | 초분광 이미지 시스템을 이용하는 정량적 세포 분석방법 | |
Shihan et al. | A simple method for quantitating confocal fluorescent images | |
JP5160158B2 (ja) | 画像化システム及びその方法 | |
CA2395627C (en) | Imaging and analyzing parameters of small moving objects such as cells | |
AU585288B2 (en) | Fluorescence imaging system | |
JP2024019180A (ja) | マルチスペクトルサンプル画像化 | |
US6473176B2 (en) | Imaging and analyzing parameters of small moving objects such as cells | |
EP2613151B1 (en) | Method for determining cancer onset or cancer onset risk | |
US7420674B2 (en) | Method and arrangement for analyzing samples | |
WO2012060163A1 (ja) | 細胞分析装置 | |
US20130230866A1 (en) | Method for Determining Effectiveness of Medicine Containing Antibody as Component | |
JP2006119152A (ja) | 照明された試料の波長依存特性把握のための方法および装置 | |
JP2002507762A (ja) | 共焦点顕微鏡イメージングシステム | |
Kurtz et al. | Application of multiline two-photon microscopy to functional in vivo imaging | |
US20160025710A1 (en) | Internal focus reference beads for imaging cytometry | |
KR20080082650A (ko) | 2개 이상의 세포 군집을 식별하는 방법, 및 용도 | |
US20200379227A1 (en) | Method For Analyzing Fluorescent Particles in an Immunoassay | |
US20100105022A1 (en) | Analyzing biological cell material based on different interactions between illumination light and cell components | |
Lee et al. | Fast and sensitive delineation of brain tumor with clinically compatible moxifloxacin labeling and confocal microscopy | |
Mohebbi et al. | Hyperspectral imaging using intracellular spies: quantitative real-time measurement of intracellular parameters in vivo during interaction of the pathogenic fungus Aspergillus fumigatus with human monocytes | |
US11143586B2 (en) | Enhancement of fountain flow cytometry signal-to-noise ratio by reducing background light intensity | |
CA2401614C (en) | Imaging and analyzing parameters of small moving objects such as cells | |
US11452478B2 (en) | System and method for detecting alzheimer's disease | |
Andrews et al. | Large-scale visualisation of α-synuclein oligomers in Parkinson's disease brain tissue | |
Sauerbeck et al. | SEQUIN multiscale imaging of mammalian central synapses reveals loss of synaptic microconnectivity resulting from diffuse traumatic brain injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121030 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130909 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140822 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170824 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180820 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 11 |